ISLAMABAD: A leading Russian pharmaceutical company and its Pakistani partner are set to transform the country’s diabetes care landscape with an $80 million investment over six years.

The Drug Regulatory Authority of Pakistan has shared details of the ambitious plan that promises to reduce heavy reliance on imported insulin.

Zavod Medsintez LLC, a prominent Russian firm specializing in biotechnological production of human insulin, has partnered with Genetics Pharmaceuticals Private Limited for the project.

The initiative involves constructing an aseptic filling plant in the first stage valued at approximately $20 million, to be completed by December 2028.

This facility will handle bulk import of insulin and dedicated biological unit operations for aseptic filling of insulin and its derivatives.

The second stage, worth around $60 million, targets full active pharmaceutical ingredient production by December 2031.

It includes comprehensive technology transfer covering biotechnological production of insulins from API purification through to packaging of finished products.

DRAP has conditionally fixed maximum retail prices for six insulin products from the Russian firm, including Rosinsulin C 100IU/ml and Insulin Isophane variants.

The pricing approval is explicitly tied to the companies commencing immediate construction of local manufacturing plants.

Pakistan faces one of the world’s most severe diabetes burdens, with the International Diabetes Federation estimating 34.5 million adults affected in 2024.

This represents a prevalence rate of 31.4 percent among adults aged 20-79, the highest globally in percentage terms.

Projections indicate the number could rise to 70.2 million by 2050 if current trends continue unchecked.

Currently, over 87 percent of insulin products in the Pakistani market are manufactured by foreign multinational companies.

Local production accounts for only about 12 percent, limited mostly to human insulin formulations while analog insulins remain dominated by imports.

Studies show that in the public sector, availability of insulin rarely exceeds 50 percent in health facilities.

None of the insulin products achieve the ideal 80 percent availability benchmark across surveyed sites.

Analog insulin products are reported to be 72.8 percent more expensive than human insulin options.

The median price of biosimilar insulin is 25.4 percent lower than originator brands, highlighting potential savings through local manufacturing.

Pakistan’s diabetes-related healthcare expenditure stood at $2.6 billion in 2021 and is projected to reach $4.4 billion by 2045.

This massive economic burden underscores the urgency of local production to improve affordability and access.

Regional media reports, including those from Business Recorder and Pakistan Today, confirm the DRAP notification linking price approvals directly to the investment commitment.

The partnership builds on earlier high-level discussions between Pakistani and Russian officials focused on pharmaceutical cooperation.

Genetics Pharmaceuticals, based in Lahore, already holds registration for importing insulin from Zavod Medsintez.

Zavod Medsintez, established in 2003 in Russia’s Ural region, pioneered commercial production of genetically engineered human insulin in the country.

The firm operates under international GMP standards and has expanded into various biologics, including insulins meeting domestic needs in Russia.

Experts view the $80 million project as a significant step toward self-reliance in critical biologics.

Local manufacturing could potentially lower costs, enhance supply chain security, and create skilled jobs in the pharmaceutical sector.

Completion of both stages by 2031 is expected to enable Pakistan to produce insulin from active ingredients domestically for the first time at this scale.

Health advocates emphasize that increased local capacity will address chronic shortages and high out-of-pocket expenses for patients.

With diabetes affecting nearly one in three adults, the initiative arrives at a critical juncture for public health.

The two-stage approach allows phased technology transfer, minimizing risks while building local expertise.

Observers note that successful implementation could encourage further foreign investments in Pakistan’s pharmaceutical industry.

The project aligns with broader government efforts to promote local production of essential medicines.

DRAP’s conditional pricing mechanism serves as a regulatory tool to ensure commitment to manufacturing milestones.

If targets are met, the venture could substantially reduce Pakistan’s dependence on imported insulin, currently supplied largely by three major global multinationals.

Patients and physicians alike anticipate improved availability and potentially more competitive pricing in the coming years.

This development marks a notable advancement in Pakistan-Russia health sector collaboration.